QSAM Biosciences (QSAM Biosciences) Debt-to-Equity : 0.01 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is QSAM Biosciences Debt-to-Equity?

QSAM Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.01 Mil. QSAM Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. QSAM Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $0.67 Mil. QSAM Biosciences's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for QSAM Biosciences's Debt-to-Equity or its related term are showing as below:

QSAM' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.06 Med: -0.65 Max: 2.08
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of QSAM Biosciences was 2.08. The lowest was -1.06. And the median was -0.65.

QSAM's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs QSAM: 0.01

QSAM Biosciences Debt-to-Equity Historical Data

The historical data trend for QSAM Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QSAM Biosciences Debt-to-Equity Chart

QSAM Biosciences Annual Data

Trend

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.69

-0.92

2.08

-0.37

0.01

QSAM Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-0.37	-1.14	-0.01	-0.01	0.01

Competitive Comparison of QSAM Biosciences's Debt-to-Equity

For the Biotechnology subindustry, QSAM Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

QSAM Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QSAM Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where QSAM Biosciences's Debt-to-Equity falls into.

QSAM Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

QSAM Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.008	+	0)	/	0.672
	=	0.01

QSAM Biosciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.008	+	0)	/	0.672
	=	0.01

QSAM Biosciences (OTCPK:QSAM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

QSAM Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of QSAM Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

QSAM Biosciences (QSAM Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » QSAM Biosciences Inc (OTCPK:QSAM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

9442 Capital of Texas Highway North, Plaza 1, Suite 500, Austin, TX, USA, 78759

Website

https://www.qsambio.com

QSAM Biosciences Inc is a clinical-stage novel radiopharmaceutical company. The company is developing treatments for bone cancer and related diseases.

Executives

Adam King	officer: Chief Financial Officer	9442 CAPITAL OF TEXAS HWY N, PLAZA 1, SUITE 500, AUSTIN TX 78759
Link Jr. Charles J	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Adriann Sax	director	7 DORSET COURT,, EAST BRUNSWICK, NJ 08816
David Charles Link	director	2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Douglas R Baum	director, officer: CEO & Director	5000 RAFFEE COVE, AUSTIN TX 78731-1132
C Richard Piazza	director, officer: Executive Chairman	2236 EAST MALL, SUITE 208, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER A1 V6T 1Z3
Checkmate Strategic Capital Holdings, Llc	other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Strategic Capital 2, Llc	10 percent owner, other: See Explanation of Responses	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Capital Group, Llc	10 percent owner, other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Charles Thomas Paschall	other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Christopher M. Nelson	director, officer: General Counsel	420 ROYAL PALM WAY, SUITE #100, PALM BEACH FL 33480
Scott W. Whitney	director, other: Former Director	96 WINDSOR DRIVE, PINE BROOK NJ 07058
Kevin Bolin	director, officer: Former Chairman & CEO	1081 ROSEDALE DRIVE, ATLANTA GA 30306
Tristan Peitz	director, other: Former Director	C/O Q2POWER TECHNOLOGIES, INC., 420 ROYAL PALM WAY, #100, PALM BEACH FL 33480
Joel David Mayersohn	director	350 EAST LAS OLAS BLVD. #1150, FORT LAUDERDALE FL 33301